Comparison of insulin glargine and insulin degludec in type 2 diabetes by continuous glucose monitoring system
Not Applicable
Recruiting
- Conditions
- type 2 diabetes
- Registration Number
- JPRN-UMIN000010715
- Lead Sponsor
- Mie Chuo Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
(1)patient with poor glycemic control (2)Type 1 diabetes (3)secondary diabetes (4)unstable diabetic complication active proliferative retinopaty untreated cardiovascular disease (5) Patient hospitalized or changed treartment within three months (6) noncompliance Irregular life (Night shift pursuer) (7)not willing to use CGM, SMBG (8)Judged as ineligible by clinical investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method glycemic variability by continuous glucose monitoring system
- Secondary Outcome Measures
Name Time Method BMI,HbA1c,glycated albumin,1,5-AG QOL(ITR-QOLN),
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the pharmacokinetic and pharmacodynamic differences between insulin glargine and degludec in type 2 diabetes management?
How does the efficacy of insulin glargine versus insulin degludec impact nocturnal glucose variability in type 2 diabetes patients?
Are there specific genetic biomarkers that predict differential response to insulin glargine or degludec in type 2 diabetes?
What are the comparative adverse event profiles of insulin glargine and degludec in type 2 diabetes, and how are hypoglycemia risks managed?
How do the glucose-lowering effects of insulin glargine and degludec compare to other long-acting insulins in type 2 diabetes treatment?